ID Week 2022
October 19 - 23, 2022
Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model
Development of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for Gram-Negative Bacteria on MicroScan Dried Gram-Negative MIC Panels
Antimicrobial Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
Cefepime -Taniborbactam: Addressing Current and Future Antimicrobial Resistance
A phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
ASM Microbe 2022
October 12, 2022
April 23 - 26, 2022
P0633 - Antimicrobial activity of cefepime in combination with taniborbactam against resistant clinical isolates of Enterobacterales from 2018-2020 global surveillance
September 29 - October 3, 2021
Oral Presentation 133 – ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
Poster Presentation 642 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation
Poster Presentation 1055 – ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
Poster Presentation 1253 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
Poster Presentation #1286 – Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
Poster Presentation 1293 – In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
July 9 - 12, 2021
Abstract 02128 – Cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent activity vs. Enterobacterales with blaOXA-48
Abstract 02144 – Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States
Abstract 02564 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against a European 2018-2020 Surveillance Collection of Pseudomonas aeruginosa
Abstract 02581 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2020 Surveillance
Abstract 03198 – Evaluation of the in vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales recovered in Spain
Abstract 03200 – Exploring the in vitro activity of cefepime/taniborbactam combination against metallo beta-lactamase producing Klebsiella pneumoniae and Pseudomonas aeruginosa isolates
Abstract 03285 – Assessment of activity of a novel orally bioavailable β-lactam/β-lactamase inhibitor combination, ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) against Enterobacterales carrying blaOXA-48
Abstract 03578 – Activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) and comparators against NDM-producing Enterobacterales from a regional outbreak
International Liver Congress 2021
June 23 - 26, 2021
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
World Microbe Forum 2021
June 20 - 24, 2021
Association of Cefepime-Taniborbactam MICs and β-lactam Resistance Mechanisms Identified Using Whole Genome Sequencing of Ertapenem-nonsusceptible Enterobacterales Clinical Isolates: CANWARD 2007-2018
October 21 - 25, 2020
Poster 1263 - Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-Beta-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
Poster 1318 - Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
April 18 - 21, 2020
P0284 – A multi-site study comparing a commercially-prepared dried MIC susceptibility system to the CLSI/ISO broth microdilution method for cefepime-taniborbactam (formerly cefepime/VNRX-5133) using Gram-negative non-fastidious organisms
P2737 - Antimicrobial Activity of Cefepime in Combination with Taniborbactam(formerly VNRX-5133) against a European 2018-2019 Surveillance Collection of Pseudomonas aeruginosa
P2738 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2019 Surveillance
ASM Microbe 2019
June 23, 2019
SUNDAY - AAR-719 - Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases
SUNDAY - AAR-720 - The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes.
SUNDAY - AAR-722 - Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of
SUNDAY - AAR-723 - Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast.
SUNDAY - AAR-726 - Efficacy of Ceftibuten + VNRX-7145, a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Model
SUNDAY - AAR-727 - Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten (CTB)/VNRX-7145 Combination against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) in the Neutropenic Murine Thigh Infection Model
SUNDAY - AAR-728 - Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates
SUNDAY - CPHM-860 - Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145 ECCMID 2019
April 13 - 16, 2019
#P1175 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of clinical isolates.
#P1176 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of beta-lactamase-producing Enterobacteriaceae.
#P1178 — VNRX-5133 maintains potent inhibitory activity in engineered NDM-1 variants with increased cefepime hydrolytic efficiency.
#P1179 — Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
#P1181 — Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145.
#P1182 — Ceftibuten/VNRX-7145, an orally bioavailable beta-lactam/beta-lactamase inhibitor combination active against serine-beta-lactamase producing Enterobacteriaceae.
#P1951 — Pharmacokinetics of VNRX-5133 in Combination with Cefepime and Metronidazole.
October 3 - 7, 2018
Poster 1360 – Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes.
K. pneumoniae and P. aeruginosa.
Poster 1370 – Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant
Poster 1395 – Defining the Magnitude of AUC:MIC Driver for Efficacy of the beta-lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-producing Enterobacteriaceae and
Poster 1401 – A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects.
Poster 1405 – Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine beta-lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model.
ASM Microbe 2018
June 7 - 11, 2018
FRIDAY 226 — Development of CLSI MIC and disk diffusion quality control ranges for Cefepime/VNRX-5133.
FRIDAY 610 — Cefepime/VNRX-5133 retains potent activity against KPC variants responsible for recent clinical treatment failures of Ceftazidime/Avibactam in
FRIDAY 611 — Evaluation of the Impact of Variation in Standard Testing Parameters on the Activity of Cefepime in Combination with VNRX-5133.
E. coli in a murine UTI model
FRIDAY 612 — Efficacy of cefepime combined with VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, against a cephalosporin-resistant ESBL
April 21 - 24, 2018
#O0575 — Pharmacodynamics of the novel broad-spectrum beta-lactamase inhibitor VNRX-5133 in combination with cefepime in neutropenic female CD-1 mice with experimental pneumonia.
#O0603 — Structural basis for serine- and metallo-beta-lactamase inhibition by VNRX-5133, a new beta-lactamase inhibitor (BLI) in clinical development.
#O0606 — Kinetic mechanism and parameters of inhibition of serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum beta-lactamase inhibitor VNRX-5133.
#P1536 — Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known beta-lactamases.
in vitro infection model.
#P1537 — Pharmacokinetics-pharmacodynamics (PK-PD) of VNRX-5133, a broad-spectrum novel beta-lactamase inhibitor (BS-BLI), in combination with cefepime in a one-compartment
#P1538 — Efficacy of cefepime / VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, in a murine bacteremia infection model with carbapenem-resistant Enterobacteriaceae (CREs).
#P1541 | Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant Enterobacteriaceae producing serine- and metallo-beta-lactamases.
#P1543 | Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates.